Akeso shares plunge 31.8% after FDA rejects ivonescimab application
Published 2 d ago2 sourcesEvidence: Reported
The FDA has disclosed its complete response letter detailing reasons for rejecting Summit Therapeutics' closely watched lung cancer drug. The rejection is a setback for the biotech's lead candidate, and the disclosed rationale will shape the company's path to resubmission. The decision is significant for Summit's valuation and for the competitive landscape in lung cancer therapeutics.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago3 sourcesEvidence: Reported
Published 12 h ago3 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported